PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Kleczkowska, Patrycja ^a   Kosson, Piotr ^a   Ballet, Steven ^b   Van den Eynde, Isabelle ^b   Tsuda, Yuko ^c   Tourwé, Dirk ^b   Lipkowski, Andrzej W ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINOCICEPTIVE AGENT; MORPHINE; NALTREXONE; NEUROTENSIN; OPIATE; PEPTIDE PK20; UNCLASSIFIED DRUG; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT; OPIATE PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TAIL FLICK TEST; ANIMAL; CHEMISTRY; DRUG DESIGN; PAIN; SYNTHESIS;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; DRUG DESIGN; NEUROTENSIN; OPIOID PEPTIDES; PAIN; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649697215     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-6-86     Document Type: Article

References (30)

1. Lipkowski AW, Misicka A, Hruby VJ, Carr DB. Opioid peptide analogues: Reconsideration as a potentially new generation of analgesics. Polish J Chem 1994, 68:907-912.
2. Kosson D, Maszczynska Bonney I, Carr DB, Mayzner-Zawadzka E, Lipkowski AW. Antinociceptive properties of biphalin after intrathecal application in rats: a reevaluation. Pharmacol Rep 2005, 57:545-549.
3. Maszczynska Bonney I, Foran SE, Marchand JE, Lipkowski AW, Carr DB. Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties. Eur J Pharmacol 2004, 488:91-99. 10.1016/j.ejphar.2004.02.023, 15044040.
4. Foran SE, Carr DB, Lipkowski AW, Maszczyńska I, Marchand JE, Misicka A, Beinborn M, Kopin A, Kream RM. Substance P - opioid chimeric peptide as a novel non-tolerance forming analgesic. Proc Natl Acad Sci USA 2000, 97:7621-7626. 10.1073/pnas.130181897, 16595, 10852965.
5. Lee YS, Agnes RS, Davis P, Ma SW, Badghisi H, Lai J, Porreca F, Hruby VJ. Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem 2007, 50:165-168. 10.1021/jm061268p, 2365893, 17201419.
6. Yano K, Kimura S, Imanishi Y. Simultaneous activation of two different receptor systems by enkephalin/neurotensin conjugates having spacer chins of various lengths. Eur J Pharm Sci 1998, 7:41-48. 10.1016/S0928-0987(98)00002-5, 9845776.
7. Binder EB, Kinkead B, Owens MJ, Nemeroff CB. Neurotensin and dopamine interactions. Pharmacol Rev 2001, 53:453-486.
8. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973, 248:6854-6861.
9. Carraway R, Leeman SE. The amino acid sequence of a hypothalamic peptide, neurotensin. J Biol Chem 1975, 250:1907-1911.
10. Hermans E, Malateaux JM. Mechanism of regulation of neurotensin receptors. Pharmacol Ther 1998, 79:89-104. 10.1016/S0163-7258(98)00009-6, 9749878.
11. Dobner PR. Neurotensin and pain modulation. Peptides 2006, 27:2405-2414. 10.1016/j.peptides.2006.04.025, 16870306.
12. Gui X, Carraway RE, Dobner PR. Endogenous neurotensin facilitates visceral nociception and is required for stress-induced antinociception in mice and rats. Neurosci 2004, 126:1023-1032.
13. Smith DJ, Hawranko AA, Monroe PJ, Gully D, Urban MO, Craig CR, Smith JP, Smith DL. Dose-dependent pain-facilitatory and -inhibitory actions of neurotensin are revealed by SR 48692, a nonpeptide neurotensin antagonist: influence on the antinociceptive effect of morphine. J Pharmacol Exper Ther 1997, 282:899-908.
14. Buhler AV, Proudfit HK, Gebhart GF. Neurotensin-produced antinociception in the rostral ventromedial medulla is partially mediated by spinal cord norepinephrine. Pain 2008, 135:280-290. 10.1016/j.pain.2007.06.010, 2423280, 17664042.
15. Horvath G, Kekesi G. Interaction of endogenous ligands mediating antinociception. Br Res Rev 2006, 52:69-92.
16. Clineschmidt BV, McGuffin JC, Bunting PB. Neurotensin: antinocisponsive action in rodents. Eur J Pharmacol 1979, 54:129-139. 10.1016/0014-2999(79)90415-1, 421735.
17. Holmes BB, Rady JJ, Smith DJ, Fujimoto JM. Supraspinal neurotensin-induced antianalgesia in mice is mediated by spinal cholecystokinin. Jpn J Pharmacol 1999, 79:141-149. 10.1254/jjp.79.141, 10202849.
18. Tyler-McMahon B, Boules M, Richelson E. Neurotensin: peptide for the next millennium. Reg Peptides 2000, 93:125-136.
19. Boules M, Frederickson P, Richelson E. Bioactive analogs of neurotensin: focus on CNS effects. Peptides 2006, 27:2523-2533. 10.1016/j.peptides.2005.12.018, 16882457.
20. Bruehlmeier M, Garcia-Garayoa E, Blanc A, Holzer B, Gergely S, Tourwé D, Schubiger PA, Bläuenstein P. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding. Nucl Med Biol 2002, 29:321-327. 10.1016/S0969-8051(01)00304-3, 11929702.
21. Kokko KP, Hadden MK, Price KL, Orwig KS, See RE, Dix TA. In vivo behavioural effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier. Neuropharmacol 2005, 48:417-425.
22. Granier C, van Rietschoten J, Kitabgi P, Poustis C, Freychet P. Synthesis and characterization of neurotensin analogue for structure-activity relationship studies. Eur J Biochem 1982, 124:117-125. 10.1111/j.1432-1033.1982.tb05913.x, 7084220.
23. Tyler BM, Douglas CL, Fauq A, Ping-Pang Y, Stewart JA, Cusack B, McCormick DJ, Richelson E. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacol 1999, 38:1027-1034.
24. Kleczkowska P, Kaczorowska E, Ruszczyńska-Bartnik K, Ejchart A, Tourwé D, Lipkowski AW. Chimeric opioid-neurotensin ligands as new prospective analgesics in chronic pain. Peptides 2008 Chemistry of Peptides in Life Science Technology and Medicine (Proceeding of the 30th European Peptide Symposium) 2008, 538-539. FIPS, Helsinki, Lankinen H, Vallivirta J, Strandin T, Hepojoli J.
25. Garcia-Garayoa E, Bläuenstein P, Bruehlmeier M, Blanc A, Iterbeke K, Conrath P, Tourwé D, Schubiger PA. Preclinical evaluation of a new stabilized neurotensin(8-13) pseudopeptide radiolabeled with 99mTc. J Nucl Med 2002, 43:374-383.
26. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976, 17:1031-1036. 10.1016/0031-9384(76)90029-9, 14677603.
27. Yoburn BC, Morales R, Kelly DD, Inturrisi CE. Constrain of the tail-flick assay: morphine analgesia and tolerance are dependent upon locus of tail stimulation. Life Sci 1984, 34:1755-1762. 10.1016/0024-3205(84)90575-7, 6727545.
28. Mazella J, Vincent JP. Functional roles of the NTS2 and NTS3 receptors. Peptides 2006, 27:2469-2475. 10.1016/j.peptides.2006.04.026, 16872720.
29. Gallagher RM, Rosenthal LJ. Chronic pain and opiates: balancing pain control and risks in long-term opioid treatment. Arch Phys Med Rehabil 2008, 89(Suppl 1):77-82.
30. Haghparast A, Semnanian S, Fathollahi Y. Morphine tolerance and dependence in the nucleus paragigantocellularis: single unit recording study in vivo. Brain Res 1998, 814:71-77. 10.1016/S0006-8993(98)01029-4, 9838050.